4895 related articles for article (PubMed ID: 6192770)
21. Serological and immunochemical analysis of the specificity of xenoantiserum 8986 elicited with hybrids between human melanoma cells and murine fibroblasts.
Imai K; Galloway DR; Ferrone S
Cancer Res; 1981 Mar; 41(3):1028-33. PubMed ID: 6161692
[TBL] [Abstract][Full Text] [Related]
22. [Can monoclonal antibodies to a carcinoma-specific cell surface molecule prevent liver metastasis of human colorectal carcinoma and effectively treat already existing micrometastases?].
Burkart C; Porschen R
Z Gastroenterol; 1996 Jan; 34(1):41-2. PubMed ID: 8776175
[No Abstract] [Full Text] [Related]
23. Dynamic interaction of 111indium-labeled monoclonal antibodies with surface antigens of solid tumors visualized in vivo by external scintigraphy.
Hwang KM; Keenan AM; Frincke J; David G; Pearson J; Oldham RK; Morgan AC
J Natl Cancer Inst; 1986 May; 76(5):849-55. PubMed ID: 3457973
[TBL] [Abstract][Full Text] [Related]
24. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
25. Biologic characterization of melanoma tumors by antigen-specific targeting of radiolabeled anti-tumor antibodies.
Larson SM
J Nucl Med; 1991 Feb; 32(2):287-91. PubMed ID: 1992033
[No Abstract] [Full Text] [Related]
26. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical reactivity of anti-melanoma monoclonal antibody 225.28S in human breast cancer biopsies.
Dell'Erba L; Calo-Gabrieli G; Caruso ML; Thomas R; Cortino G; Valentini AM; Muto P; Albrizio M; Pastena MI; Lastoria S
Anticancer Res; 2001; 21(2A):925-30. PubMed ID: 11396186
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody-defined antigens on tumor cells.
Baldwin RW; Embleton MJ; Price MR
Biomembranes; 1983; 11():285-312. PubMed ID: 6338949
[No Abstract] [Full Text] [Related]
29. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
Lin K; Nagy JA; Xu H; Shockley TR; Yarmush ML; Dvorak HF
Cancer Res; 1994 Apr; 54(8):2269-77. PubMed ID: 8174137
[TBL] [Abstract][Full Text] [Related]
30. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
31. Studies of a high molecular weight human melanoma-associated antigen.
Hellström I; Garrigues HJ; Cabasco L; Mosely GH; Brown JP; Hellström KE
J Immunol; 1983 Mar; 130(3):1467-72. PubMed ID: 6822741
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
Retter MW; Johnson JC; Peckham DW; Bannink JE; Bangur CS; Dresser K; Cai F; Foy TM; Fanger NA; Fanger GR; Woda B; Rock KL
Cancer Res; 2005 Jul; 65(14):6425-34. PubMed ID: 16024647
[TBL] [Abstract][Full Text] [Related]
33. Human tumor-associated antigens defined by monoclonal antibodies.
Reisfeld RA; Harper JR; Bumol TF
Crit Rev Immunol; 1984; 5(1):27-53. PubMed ID: 6400468
[TBL] [Abstract][Full Text] [Related]
34. Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody.
Yeh MY; Hellström I; Hellström KE
J Immunol; 1981 Apr; 126(4):1312-7. PubMed ID: 7009737
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies to human mammary carcinoma associated antigens and their potential uses for diagnosis, prognosis, and therapy.
Colcher D; Hand PH; Wunderlich D; Nuti M; Teramoto YA; Kufe D; Schlom J
Lab Res Methods Biol Med; 1983; 8():215-58. PubMed ID: 6358744
[No Abstract] [Full Text] [Related]
36. Recognition and destruction of target cells by tumoricidal macrophages.
Fidler IJ
Isr J Med Sci; 1978 Jan; 14(1):177-91. PubMed ID: 204610
[No Abstract] [Full Text] [Related]
37. A melanosomal membrane protein is a cell surface target for melanoma therapy.
Takechi Y; Hara I; Naftzger C; Xu Y; Houghton AN
Clin Cancer Res; 1996 Nov; 2(11):1837-42. PubMed ID: 9816138
[TBL] [Abstract][Full Text] [Related]
38. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
Takahashi T; Irie RF; Morton DL; Hoon DS
Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
[TBL] [Abstract][Full Text] [Related]
39. Higher cytolytic efficiency of an IgG2 alpha than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen.
Imai K; Pellegrino MA; Wilson BS; Ferrone S
Cell Immunol; 1982 Sep; 72(2):239-47. PubMed ID: 6185235
[No Abstract] [Full Text] [Related]
40. Spectrum of melanoma antigens on cultured human malignant melanoma cells as detected by monkey antibodies.
Liao SK; Kwong PC; Thompson JC; Dent PB
Cancer Res; 1979 Jan; 39(1):183-92. PubMed ID: 83908
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
